KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Common Equity (2016 - 2025)

Sarepta Therapeutics has reported Common Equity over the past 15 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly results put Common Equity at $1.1 billion for Q4 2025, down 25.34% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (down 25.34% YoY), and the annual figure for FY2025 was $1.1 billion, down 25.34%.
  • Common Equity for Q4 2025 was $1.1 billion at Sarepta Therapeutics, down from $1.3 billion in the prior quarter.
  • Over the last five years, Common Equity for SRPT hit a ceiling of $1.5 billion in Q4 2024 and a floor of $385.0 million in Q4 2022.
  • Median Common Equity over the past 5 years was $858.1 million (2022), compared with a mean of $882.2 million.
  • Biggest five-year swings in Common Equity: tumbled 58.52% in 2022 and later skyrocketed 123.23% in 2023.
  • Sarepta Therapeutics' Common Equity stood at $928.0 million in 2021, then tumbled by 58.52% to $385.0 million in 2022, then soared by 123.23% to $859.3 million in 2023, then skyrocketed by 77.78% to $1.5 billion in 2024, then decreased by 25.34% to $1.1 billion in 2025.
  • The last three reported values for Common Equity were $1.1 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.4 billion (Q2 2025) per Business Quant data.